Pharma Worried By EMA’s Stricter Approach To New Active Substance Claims For Biologics

EFPIA says the European Medicines Agency’s proposed criteria for determining “new active substance” status for biologicals may encourage subjective assessments and result in a higher standard for grant of the status.